- Henry Schein, Inc. has announced that after its May 21, 2026 Annual Meeting, its Board of Directors will shrink from fifteen to ten members as long-serving director Stanley M. Bergman retires and four other directors do not stand for reelection.
- This major board reshaping coincides with anticipation around the company’s upcoming first-quarter 2026 earnings, where analysts are expecting higher profits despite ongoing pressures in its core dental segment.
- Next, we’ll examine how this significant Board reshaping, including Stanley M. Bergman’s retirement, could influence Henry Schein’s broader investment narrative.
The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Henry Schein Investment Narrative Recap
To own Henry Schein, you need to believe its pivot toward higher margin technology, specialty products and services can offset headwinds in its core dental distribution business. The upcoming first quarter 2026 earnings remain the key short term catalyst, with profit expectations in focus against soft dental demand and margin pressure. The planned reduction of the Board from fifteen to ten members, alongside Stanley Bergman’s retirement, is meaningful for governance but does not, on its own, materially change those near term business risks.
The most relevant recent announcement alongside this Board reshaping is the 2026 earnings guidance, which points to expected total sales growth of about 3% to 5% over 2025. That outlook is closely tied to the same issues driving near term expectations today: execution on cost savings and value creation projects with KKR, growth in higher margin specialties and technology, and the company’s ability to manage ongoing pressure in dental markets while pursuing operating margin improvement.
Yet behind Henry Schein’s steady Board reshaping, the execution risk around its multi year value creation and cost savings program is something investors should be very aware of...
Read the full narrative on Henry Schein (it's free!)
Henry Schein's narrative projects $14.7 billion revenue and $595.4 million earnings by 2029.
Uncover how Henry Schein's forecasts yield a $89.23 fair value, a 17% upside to its current price.
Exploring Other Perspectives
While the consensus view focuses on steady cost savings and digital growth, the most optimistic analysts were expecting revenue of about US$14.9 billion and earnings near US$660 million by 2029, so this Board overhaul and leadership transition could meaningfully shift how you weigh those upside scenarios against the risk that value creation projects under deliver.
Explore 2 other fair value estimates on Henry Schein - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Henry Schein research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Henry Schein research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Henry Schein's overall financial health at a glance.
Curious About Other Options?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Find 53 companies with promising cash flow potential yet trading below their fair value.
- AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com